Dr. Eric Schafer is a member of the Leukemia Program and the Developmental Therapeutics Program. His clinical interests include caring for children with leukemias and children with all cancer types requiring novel therapies. His research interests focus on studying the clinical development of new cancer drugs for children and exploring new ways to make older drug safer and more effective.
In addition to his training and certification in Pediatrics and Pediatric Hematology/Oncology, Dr. Schafer is fellowship trained and board certified in Clinical Pharmacology. He has used this training and interest to lead several local and national studies on standard drugs including vincristine and methotrexate and new drugs such as talazoparib and eribulin.
Dr. Schafer is an active member of the Children’s Oncology Group (COG) where he serves on protocol study committees for T cell ALL and high risk pre-B ALL and is an active member of the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium for which he serves as the Texas Children’s Cancer Center’s Principal Investigator.
American Board of Pediatrics
American Board of Pediatrics – Hematology/Oncology
American Board of Clinical Pharmacology